Morie A. Gertz, MD, MACP, professor of medicine, Mayo Clinic, discusses the current outlook for patients with Waldenström macroglobulinemia.

The median age for these patients is 73, so this is an older and can be more frail population of adults with comorbidities. Judgement is necessary in appropriately selecting a treatment regimen that will be appropriate and not cause too much toxicity for these patients.

Fortunately, Gertz says there is a host of available management tools that can effectively control disease for many years.

Videos

Morie A. Gertz, MD, MACP, discusses the current outlook for patients with Waldenström macroglobulinemia.

Morie A. Gertz, MD, MACP

Articles

Dr. Gertz on the Outlook for Waldenstrom Macroglobulinemia